4-(4-氟苯基)-2,4-二氧代丁酸甲酯 | 39757-34-1

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-(4-氟苯基)-2,4-二氧代丁酸甲酯
• 中文别名: 4-氟-A,G-二氧代-苯丁酸甲酯；4-氟苯甲酰丙酮酸甲酯
• 英文名称: methyl 4-(4-fluorophenyl)-2,4-dioxobutanoate
• CAS: 39757-34-1
• 化学式: C₁₁H₉FO₄
• mdl: MFCD04967387
• 分子量: 224.188
• InChiKey: PAEDUWHKVNTJMJ-UHFFFAOYSA-N

物化性质

• 熔点：
  120-121 °C
• 沸点：
  348.7±22.0 °C(Predicted)
• 密度：
  1.278±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  60.4
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2918300090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : METHYL 4-(4-FLUOROPHENYL)-2,4-
DIOXOBUTANOATE
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 39757-34-1
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
This substance is not classified as dangerous according to Directive 67/548/EEC.
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C11H9FO4
Molecular Weight : 224,19 g/mol
CAS-No. : 39757-34-1
No components need to be disclosed according to the applicable regulations.

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, Hydrogen fluoride
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Avoid
breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 1,073
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(4-氟苯基)-2,4-二氧代丁酸甲酯 在 一水合肼 、 溶剂黄146 作用下， 反应 1.0h， 生成 methyl 3-(4-fluorophenyl)-1H-pyrazole-5-carboxylate
  参考文献：
  名称：

  杂芳族连接的4β-酰胺基鬼臼毒素作为细胞凋亡诱导剂的合成及抗癌活性

  摘要：

  合成了一系列不同的杂芳族连接的4β-酰胺基鬼臼毒素偶联物（16a – i，17a – i和18a – d），并评估了其对五种人类癌细胞系的抗癌活性。在该系列中，一种化合物17g在A549（肺癌）细胞系中显示出显着的抗增殖活性。流式细胞仪分析表明，17g细胞在G2 / M期停滞，导致caspase-3依赖性凋亡细胞死亡。此外，Hoechst 33258染色和DNA片段化分析还表明17g通过凋亡诱导细胞死亡。

  DOI：

  10.1016/j.bmcl.2012.10.099
• 作为产物：
  描述：

  草酸二甲酯 、 4-氟苯乙酮 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 12.0h， 生成 4-(4-氟苯基)-2,4-二氧代丁酸甲酯
  参考文献：
  名称：

  发现一种有效、选择性和细胞活性的 m6A 脱甲基酶 ALKBH5 抑制剂

  摘要：

  AlkB 同系物 5 (ALKBH5) 是一种 RNA m 6 A 去甲基化酶，参与基因转录、翻译和代谢的调控，被认为是多种人类疾病，尤其是癌症的有前途的治疗靶点。然而，仍然缺乏强效和选择性的 ALKBH5 抑制剂。在此，我们报告了一类包含 1-aryl-1 H -吡唑支架的新型 ALKBH5 抑制剂，它们是通过基于荧光偏振的筛选、结构优化和构效关系分析获得的。在这些化合物中，20m是最有效的化合物，其在荧光偏振测定中显示出0.021μM的IC 50值。大院20m对 ALKBH5 与 FTO 以及其他 AlkB 亚家族成员表现出高选择性，表明对 ALKBH5 具有良好的选择性。细胞热转移试验 (CETSA) 分析表明，20m可有效稳定 HepG2 细胞中的 ALKBH5。斑点印迹实验表明，20m可以增加完整细胞中的m 6 A 水平。总的来说，20m是一种有效的、选择性的和具有细胞活性的 ALKBH5

  DOI：

  10.1016/j.ejmech.2022.114446

文献信息

• [EN] CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME<br/>[FR] COMPOSÉS DE SULFAMIDE CYCLIQUE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ASSEMBLY BIOSCIENCES INC

  公开号：WO2018160878A1

  公开（公告）日：2018-09-07

  The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.

  本公开提供了部分环磺胺化合物及其药物组合物，可用作乙型肝炎（HBV）核心蛋白的调节剂，并用于治疗乙型肝炎（HBV）感染的方法。
• Design, Synthesis, Biological Evaluation and In Silico Studies of Pyrazole-Based NH2-Acyl Oseltamivir Analogues as Potent Neuraminidase Inhibitors
  作者：Jiqing Ye、Lin Lin、Jinyi Xu、Paul Kay-sheung Chan、Xiao Yang、Cong Ma

  DOI：10.3390/ph14040371

  日期：——

  Oseltamivir represents one of the most successful neuraminidase (NA) inhibitors in the current anti-influenza therapy. The 150-cavity of NA was identified as an additional binding pocket, and novel NA inhibitors have been designed to occupy the 150-cavity based on the structure information of oseltamivir carboxylate (OC) in complex with NA. In this study, a series of C-5-NH2-acyl derivatives of OC

  奥司他韦是当前抗流感治疗中最成功的神经氨酸酶（NA）抑制剂之一。 NA 的 150 个空腔被确定为一个额外的结合袋，并且根据羧酸奥司他韦 ( OC ) 与 NA 复合物的结构信息，设计了新型 NA 抑制剂来占据 150 个空腔。本研究合成了一系列含有吡唑部分的OC的C-5-NH 2 -酰基衍生物。几种衍生物对 NA 表现出显着的抑制活性。此外，计算机ADME评估表明，该衍生物具有类似药物的特性，比OC具有更高的口服吸收率和更大的细胞渗透性。此外，分子对接研究表明，衍生物与 NA 酶活性位点和 150 腔相互作用，正如预期的那样。研究结果为OC的进一步结构优化提供了有用的信息。
• Non-peptide-based new class of platelet aggregation inhibitors: Design, synthesis, bioevaluation, SAR, and<i>in silico</i>studies
  作者：Pradeep K. Jaiswal、Vashundhra Sharma、Surendra Kumar、Manas Mathur、Ajit K. Swami、Dharmendra K. Yadav、Sandeep Chaudhary

  DOI：10.1002/ardp.201700349

  日期：2018.4

  A series of 2‐oxo‐2‐phenylethylidene linked 2‐oxo‐benzo[1,4]oxazine analogues 17a–x and 18a–o, incorporated with a variety of electron‐withdrawing as well as electron‐donating groups at ring A and ring C, were synthesized under greener conditions in excellent yields (up to 98%). These analogues 17a–x and 18a–o were evaluated for their arachidonic acid (AA)‐induced platelet aggregation inhibitory activities

  一系列 2-oxo-2-phenylethylidene 连接的 2-oxo-benzo[1,4]oxazine 类似物 17a-x 和 18a-o，在环 A 和环 C，在更环保的条件下以优异的产率（高达 98%）合成。与标准参考阿司匹林 (IC50 = 21.34 ± 1.09 µg/mL) 相比，评估了这些类似物 17a-x 和 18a-o 的花生四烯酸 (AA) 诱导的血小板聚集抑制活性。在所有筛选的化合物中，与阿司匹林相比，8 种类似物 17i、17x、18f、18g、18h、18i、18l 和 18o 被鉴定为有前途的血小板聚集抑制剂。此外，通过 MTT 分析对 3T3 成纤维细胞系进行了有希望的化合物（17i、17x、18f-18i、18l、和 18o) 并且发现这些化合物在性质上是无毒的。此外，这些化合物（17i、17x、18f-18i、18l 和 18o）的 AA 诱导的血
• Synthesis and mechanistic aspects of 2-anilinonicotinyl-pyrazolo[1,5-a]pyrimidine conjugates that regulate cell proliferation in MCF-7 cells via estrogen signaling
  作者：Ahmed Kamal、Shaikh Faazil、S.M. Ali Hussaini、M. Janaki Ramaiah、M. Balakrishna、Nibedita Patel、S.N.C.V.L. Pushpavalli、Manika Pal-Bhadra

  DOI：10.1016/j.bmcl.2016.02.072

  日期：2016.4

  pyrazolo[1,5-a]pyrimidine conjugates (6a–x) were synthesized and evaluated for their antiproliferative activity. Some of these conjugates exhibited promising cytotoxic effects in the MCF-7 cell line and among these 6a and 6c exhibited significant effects, apart from G2/M cell cycle arrest. Interestingly they showed profound effects on cyclin D1, Bcl-2 and survivin proteins that regulate breast cancer cell

  合成了一系列的壬基烟酰胺基连接的吡唑并[1,5- a ]嘧啶共轭物（6a – x），并评估了它们的抗增殖活性。这些缀合物中的一些在MCF-7细胞系中显示出有希望的细胞毒性作用，并且在这些6a和6c中，除了G2 / M细胞周期停滞外，还显示出显着的作用。有趣的是，它们对调节乳腺癌细胞增殖的cyclin D1，Bcl-2和survivin蛋白显示出深远的影响。此外，研究了ERα蛋白的表达，以了解这些偶联物在雌激素阳性乳腺癌细胞（如MCF-7和化合物6a和6c）中对雌激素活性的调节作用。 减少了他们的活动。
• Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
  申请人：G.D. Searle & Co.

  公开号：US05756529A1

  公开（公告）日：1998-05-26

  A method of using pyrazolyl benzenesulfonamide compounds in treating inflammation and inflammation-related disorders in companion animals is disclosed.

  揭示了一种在治疗伴侣动物的炎症和与炎症相关的疾病中使用吡唑基苯磺酰胺化合物的方法。